Wilson's Disease Drugs Market Report 2026

Wilson's Disease Drugs Market Overview

• Wilson's Disease Drugs market size has reached to $0.66 billion in 2025 • Expected to grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Rising Genetic Disorder Cases Fueling The Growth Of The Market Due To Increasing Inheritable Mutations • Market Trend: Advancements In Oral Formulations To Improve Wilson’s Disease Treatment Options • North America was the largest region in 2025.

What Is Covered Under Wilson's Disease Drugs Market?

Wilson’s disease drugs are medications used to manage a rare genetic condition that leads to harmful copper buildup, mainly in the liver and brain. These medications work by either enhancing copper elimination or blocking its absorption. Their primary purpose is to prevent or reverse organ damage, particularly affecting the liver and nervous system. The main types of wilson's disease drugs are chelating agents, zinc therapy, liver transplants, and symptomatic treatments. Chelating agents treat wilson's disease by binding excess copper for urinary excretion, rapidly reducing toxic buildup. It is administered through various routes of administration, such as oral, intravenous, and subcutaneous, and is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and is used by various end-users, such as hospitals, home care, specialty clinics, and others.

What Is The Wilson's Disease Drugs Market Growth Forecast?

The wilson's disease drugs market size is expected to see strong growth in the next few years. It will grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of novel chelating agents and experimental drugs, expansion of homecare services for chronic management, rising liver transplantation procedures, increasing adoption of oral and intravenous therapies, growth of specialty clinics and online pharmacy channels. Major trends in the forecast period include growing adoption of chelating agents for copper removal, rising preference for zinc-based therapies, increasing liver transplant procedures for advanced cases, expansion of symptomatic treatments for neurological manifestations, rising homecare and specialty clinic management.

Global Wilson's Disease Drugs Market Segmentation

1) By Type: Chelating Agents, Zinc Therapy, Liver Transplant, Symptomatic Treatments 2) By Route Of Administration: Oral, Intravenous, Subcutaneous 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels 4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Chelating Agents: Penicillamine, Trientine, Tetrathiomolybdate, Experimental Chelators 2) By Zinc Therapy: Zinc Acetate, Zinc Gluconate, Zinc Sulfate 3) By Liver Transplant: Orthotopic Liver Transplantation, Living Donor Liver Transplantation, Deceased Donor Liver Transplantation 4) By Symptomatic Treatments: Antipsychotic Medications, Antiepileptic Drugs, Antidepressants, Muscle Relaxants, Anticholinergics

What Is The Driver Of The Wilson's Disease Drugs Market?

The growing incidence of genetic disorders is expected to propel the growth of the wilson's disease drugs market going forward. Genetic disorders are diseases caused by abnormalities in an individual's DNA, either due to mutations, deletions, or chromosome changes. Genetic disorders are increasing mainly due to higher parental age, which raises the risk of inheritable mutations being passed to offspring. Wilson's disease drugs treat the genetic disorder by lowering harmful copper levels caused by ATP7B gene mutations. They achieve this by enhancing copper excretion or blocking its absorption, protecting vital organs such as the liver and brain. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the growing incidence of genetic disorders is driving the growth of the wilson's disease drugs industry.

Key Players In The Global Wilson's Disease Drugs Market

Major companies operating in the wilson's disease drugs market are Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Taj Pharmaceutical Limited, Biophore Pharma Inc., Orphalan SA, Nobelpharma Co. Ltd., Eton Pharmaceuticals Inc., LogicBio Therapeutics Inc., DepYmed Inc., Vivet Therapeutics SAS, Innorna, Apotex Inc., Hikma Pharmaceuticals PLC, Zydus Lifesciences Ltd., Cipla Ltd., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Strides Pharma Science Ltd., Wockhardt Ltd., Accord Healthcare Ltd., Mallinckrodt Pharmaceuticals, Meda AB, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Laurus Labs Ltd., MSN Laboratories Pvt. Ltd.

Global Wilson's Disease Drugs Market Trends and Insights

Major companies operating in the wilson's disease drug market are focusing on developing advanced drugs, such as trientine tetrahydrochloride (TETA-4HCl)-based formulations, to enhance treatment outcomes and patient convenience in managing rare diseases. A trientine tetrahydrochloride (TETA-4HCl)-based formulation refers to an advanced oral copper-chelating therapy specifically designed to maintain copper balance in adult patients with stable wilson disease. For instance, in April 2023, Orphalan SA, a France-based orphan drug development and commercialization company, launched Cuvrior. It was approved by the Food and Drug Administration (FDA) and granted Orphan Drug Exclusivity. It is a new trientine tetrahydrochloride (TETA-4HCl) intended for adults with stable wilson disease who are already decoppered and tolerant to penicillamine. It offers a room temperature-stable oral therapy that provides dosing flexibility and convenience compared to previous treatments.

What Are Latest Mergers And Acquisitions In The Wilson's Disease Drugs Market?

In January 2025, Eton Pharmaceuticals, a US-based pharmaceutical company, acquired Galzin from Teva Pharmaceuticals USA for an undisclosed amount. The acquisition aims to strengthen Eton Pharmaceuticals’s commitment to rare disease treatments by expanding its portfolio with an FDA-approved therapy for the ultra-rare metabolic condition Wilson disease. Teva Pharmaceuticals USA, Inc. is a US-based pharmaceutical company that manufactures wilson's disease drugs.

Regional Insights

North America was the largest region in the wilson's disease drugs market in 2025. The regions covered in the wilson's disease drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wilson's disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Wilson's Disease Drugs Market?

The wilson's disease drugs market consists of sales of zinc salts, penicillamine, and trientine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Wilson's Disease Drugs Market Report 2026?

The wilson's disease drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the wilson's disease drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.